Bristol-Myers Squibb Company – Consensus ‘buy’ rating and 5.7% Upside Potential

Broker Ratings

Bristol-Myers Squibb Company which can be found using ticker (BMY) have now 20 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 84.09 and 53.93 with the average target price sitting at $73.01. Given that the stocks previous close was at $69.08 and the analysts are correct then we can expect a percentage increase in value of 5.7%. Also worth taking note is the 50 day moving average now sits at $68.46 and the 200 moving average now moves to $72.15. The company has a market cap of 143.89B. The stock price is currently at: 68.06 USD

The potential market cap would be $152,072,803,115 based on the market consensus.

USD

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 19.84, revenue per share of 21.64 and a 6.04% return on assets.

Share on:
Find more news, interviews, share price & company profile here for:
    Bloomsbury Publishing Plc secures a landmark long-term supply agreement with Amazon, reaffirming expected growth and market confidence for 2025.

      Search

      Search